{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:42:02Z","timestamp":1773283322961,"version":"3.50.1"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2008,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Telavancin is an investigational, rapidly bactericidal lipoglycopeptide antibiotic that is being developed to treat serious infections caused by gram-positive bacteria. A baseline prospective surveillance study was conducted to assess telavancin activity, in comparison with other agents, against contemporary clinical isolates collected from 2004 to 2005 from across the United States. Nearly 4,000 isolates were collected, including staphylococci, enterococci, and streptococci (pneumococci, beta-hemolytic, and viridans). Telavancin had potent activity against\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            and coagulase-negative staphylococci (MIC range, 0.03 to 1.0 \u03bcg\/ml), independent of resistance to methicillin or to multiple agents. Telavancin activity was particularly potent against all streptococcal groups (MIC\n            <jats:sub>90<\/jats:sub>\n            s, 0.03 to 0.12 \u03bcg\/ml). Telavancin had excellent activity against vancomycin-susceptible enterococci (MIC\n            <jats:sub>90<\/jats:sub>\n            , 1 \u03bcg\/ml) and was active against VanB strains of vancomycin-resistant enterococci (MIC\n            <jats:sub>90<\/jats:sub>\n            , 2 \u03bcg\/ml) but less active against VanA strains (MIC\n            <jats:sub>90<\/jats:sub>\n            , 8 to 16 \u03bcg\/ml). Telavancin also demonstrated activity against vancomycin-intermediate\n            <jats:italic>S. aureus<\/jats:italic>\n            and vancomycin-resistant\n            <jats:italic>S. aureus<\/jats:italic>\n            strains (MICs, 0.5 \u03bcg\/ml to 1.0 \u03bcg\/ml and 1.0 \u03bcg\/ml to 4.0 \u03bcg\/ml, respectively). These data may support the efficacy of telavancin for treatment of serious infections with a wide range of gram-positive organisms.\n          <\/jats:p>","DOI":"10.1128\/aac.01641-07","type":"journal-article","created":{"date-parts":[[2008,4,29]],"date-time":"2008-04-29T00:53:45Z","timestamp":1209430425000},"page":"2383-2388","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":80,"title":["Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United States"],"prefix":"10.1128","volume":"52","author":[{"given":"Deborah C.","family":"Draghi","sequence":"first","affiliation":[{"name":"Eurofins Medinet, Inc., Herndon, Virginia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bret M.","family":"Benton","sequence":"additional","affiliation":[{"name":"Theravance, Inc., South San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin M.","family":"Krause","sequence":"additional","affiliation":[{"name":"Theravance, Inc., South San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clyde","family":"Thornsberry","sequence":"additional","affiliation":[{"name":"Eurofins Medinet, Inc., Herndon, Virginia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Pillar","sequence":"additional","affiliation":[{"name":"Eurofins Medinet, Inc., Herndon, Virginia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F.","family":"Sahm","sequence":"additional","affiliation":[{"name":"Eurofins Medinet, Inc., Herndon, Virginia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically 7th ed 2006"},{"key":"e_1_3_2_3_2","unstructured":"Performance standards for antimicrobial susceptibility testing 17th informational supplement 2007"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/380457"},{"key":"e_1_3_2_5_2","unstructured":"In vitro activity of telavancin against enterococci: results from the 2004-2005 U.S. Surveillance Initiative abstr. E-0717 2006"},{"key":"e_1_3_2_6_2","unstructured":"Baseline antistaphylococcal profile of telavancin: results of the 2004-2005 U.S. Surveillance Initiative abstr. E-0715 2006"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.5024-5032.2005"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.6.2149-2152.2004"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1127-1134.2005"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00100-07"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(03)00154-7"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/374052"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh156"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl235"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2003.09.002"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3602-3604.2003"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.09.025"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2006.01550.x"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/520195"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.862-867.2006"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/587896"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/429914"},{"key":"e_1_3_2_23_2","unstructured":"Baseline profile of telavancin activity against streptococci: results of the. 2004-2005 U.S. Surveillance Initiative abstr. E-0719 2006"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl093"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01641-07","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01641-07","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:49:21Z","timestamp":1645472961000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01641-07"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["10.1128\/AAC.01641-07"],"URL":"https:\/\/doi.org\/10.1128\/aac.01641-07","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7]]},"assertion":[{"value":"2007-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-04-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}